ACIU AC Immune SA - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACIU Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.52
Analyst Target
$9.13
+262.5%
Upside
52W High
$4.0
52W Low
$1.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$253.51M
P/E
N/A
ROE
-74.6%
Profit margin
N/A
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACIU's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a high target price of $9.13, the company exhibits catastrophic profitability and growth metrics—negative ROE (-74.63%), gross margin of 0.00%, and a 96.3% YoY revenue decline—undermining long-term viability. The stock trades at a premium valuation (Price/Sales: 57.99) with no earnings or cash flow support, and insider sentiment remains tepid at 40/100. These factors collectively suggest a high-risk speculative position with limited fundamental justification.
Key Strengths
Analyst consensus remains strongly positive with a 'strong_buy' rating and a $9.13 target price
Recent quarterly earnings have shown some improvement in EPS surprise (e.g., +23.8% Q/Q growth)
Low debt/equity ratio (0.07) indicates minimal leverage risk
Current and quick ratios (1.16 and 1.12) suggest short-term liquidity adequacy
Insider sentiment is neutral-to-positive (40/100), indicating no large-scale selling
Key Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
96.3% YoY revenue decline and negative operating margin (-1671.88%) indicate business contraction
No positive profitability metrics: ROE, ROA, and gross margin are all negative or zero
Absence of Altman Z-Score raises unquantified bankruptcy risk; financial health is fragile
Stock trades at an extreme Price/Sales of 57.99, far above peers and justified only by speculative growth hopes
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
20
40
25
15
0
AI Verdict
High Risk
Key drivers: Extremely low Piotroski F-Score (1/9), Catastrophic revenue and earnings decline, Negative profitability across all key metrics, Premium valuation with no earnings support, Absence of Altman Z-Score increases distress risk
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 57.99 is extremely high for a company with no revenue growth
- No Graham Number or intrinsic value estimate available
- Forward P/E of -3.42 indicates no earnings in the near term
- Valuation is not supported by fundamentals
Future
40/100
Ref Growth rates
Positives
- Analyst target price implies significant upside (from $2.52 to $9.13)
- Recent Q/Q EPS growth of +23.8% suggests potential turnaround
- Some positive earnings surprises in recent quarters
Watchpoints
- 96.3% YoY revenue decline indicates ongoing business deterioration
- No positive earnings growth over multiple periods
- Forward P/E remains negative, signaling continued losses
Past
25/100
Ref Historical trends
Positives
- Some quarters have beaten estimates (e.g., +125.9% surprise in Q4 2024)
- Historical EPS has shown volatility but occasional improvement
Watchpoints
- Consistent negative earnings over 25 quarters
- Average earnings surprise of -4.41% over last 4 quarters
- Most recent earnings were significantly below expectations
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity (0.07) and healthy current/quick ratios (1.16/1.12)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but financial health is critically weak
- Negative ROE (-74.63%) and ROA (-21.96%) reflect poor capital efficiency
- Operating margin of -1671.88% is unsustainable
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.52
Analyst Target
$9.13
Upside/Downside
+262.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACIU and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACIU
AC Immune SA
Primary
|
-68.5% | +13.5% | -5.3% | +17.2% | -25.9% | -15.7% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-89.2% | -61.8% | -56.8% | -49.6% | +15.8% | +3.3% |
|
ALEC
Alector, Inc.
Peer
|
-90.7% | -79.9% | +9.5% | -8.8% | +11.4% | +3.7% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.8% | -57.7% | -35.7% | -24.4% | -11.1% | +6.2% |
|
AMRN
Amarin Corporation plc
Peer
|
-91.1% | -66.3% | +29.4% | -1.6% | +5.1% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.42
PEG Ratio
N/A
P/B Ratio
3.16
P/S Ratio
57.99
EV/Revenue
34.64
EV/EBITDA
-2.11
Market Cap
$253.51M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1671.88%
Gross Margin
N/A
ROE
-74.63%
ROA
-21.96%
Growth
Revenue and earnings growth rates
Revenue Growth
-96.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
1.16
Good
Quick Ratio
1.12
Good
Cash/Share
$1.07
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-12
$N/A
2025-11-04
$-0.16
+7.8% surprise
2025-08-05
$-0.21
-29.2% surprise
2025-04-30
$-0.19
+8.2% surprise
Healthcare Sector Comparison
Comparing ACIU against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-74.63%
This Stock
vs
-56.86%
Sector Avg
+31.2%
(Excellent)
Debt to Equity
0.07
This Stock
vs
2.68
Sector Avg
-97.2%
(Less Debt)
Revenue Growth
-96.3%
This Stock
vs
62.23%
Sector Avg
-254.7%
(Slower)
Current Ratio
1.16
This Stock
vs
3.45
Sector Avg
-66.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACIU
AC Immune SA
|
BEARISH | $253.51M | - | -74.6% | -% | $2.52 | |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $213.96M | - | -27.4% | -68.3% | $7.53 | |
|
ALEC
Alector, Inc.
|
BEARISH | $213.94M | - | -122.0% | -156.0% | $1.96 | |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $213.79M | - | -15.5% | -22.5% | $3.77 | |
|
AMRN
Amarin Corporation plc
|
BEARISH | $306.69M | - | -17.4% | -38.0% | $14.75 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
BTIG
2025-11-04
Buy
Buy
BTIG
2025-09-08
Buy
Buy
Past News Coverage
Recent headlines mentioning ACIU from our newsroom.
Newest → oldest
No matching news yet.